🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05647109
Recruiting Observational

Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer

NCT05647109 · tracked via the Priya Life Science China tracker
Sponsor
Peking University People's Hospital
Phase
Observational
Started
2021-09-01
Last updated
2025-05-04

Condition(s) studied

Endometrial Carcinoma Stage IAtypical Endometrial Hyperplasia

Investigational drug(s) / intervention(s)

No intervention

No intervention: No intervention

Study summary

To construct a prediction model of progesterone sensitivity in patients with endometrial cancer treated with fertility preservation

Eligibility

Sex
FEMALE
Min age
17 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Have a confirmed pathological diagnosis based upon hysteroscopy: atypical endometrial hyperplasia or histologically prove well-differentiated EEC G1 without myometrial invasion * No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound * Have a desire for remaining reproductive function or uterus * Good compliance with adjunctive treatment and follow-up Exclusion Criteria: * Acute liver disease or liver tumor (benign or malignant) or renal dysfunction * Pregnancy or potential pregnancy * Confirmed diagnosis of any cancer in reproductive system * Acute severe disease such as stroke or heart infarction or a history of thrombosis disease * Hypersensitivity or contradiction for using MPA or MA * With other factors of reproductive dysfunction; * Strong request for uterine removal or other conservative treatment

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University People's Hospital Beijing Beijing Municipality Recruiting

More Peking University People's Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05647109 on ClinicalTrials.gov ↗ ← All trials in China